36It should be added that, with regard to the objective of Regulation No 469/2009, it is clear from the wording of recitals 3 to 5 and 9 thereof, as the Advocate General observed in point 50 of his Opinion, that the SPC regime has the purpose of compensating for the lack of protection conferred by a patent with respect to covering the investment put into research concerning new medicinal products and, therefore, of encouraging that research. However, it follows from recital 10 of that regulation that the legislature intended to achieve that objective so as to take into account all the interests at stake, including those of public health, in a sector as complex and sensitive as the pharmaceutical sector.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.